References
- Redston MS, Wanless IR. The hepatic von Meyenburg complex: prevalence and association with hepatic and renal cysts among 2843 autopsies [corrected]. Mod Pathol. 1996;9:233–237.
- Horton KM, Bluemke DA, Hruban RH, et al. CT and MR imaging of benign hepatic and biliary tumors. Radiographics. 1999;19:431–451.
- Lev-Toaff AS, Bach AM, Wechsler RJ, et al. The radiologic and pathologic spectrum of biliary hamartomas. AJR Am J Roentgenol. 1995;165:309–313.
- Zen Y, Terahata S, Miyayama S, et al. Multicystic biliary hamartoma: a hitherto undescribed lesion. Hum Pathol. 2006;37:339–344.
- Xu AM, Xian ZH, Zhang SH, et al. Intrahepatic cholangiocarcinoma arising in multiple bile duct hamartomas: report of two cases and review of the literature. Eur J Gastroenterol Hepatol. 2009;21:580–584.
- Kim HK, Jin SY. Cholangiocarcinoma arising in von Meyenburg complexes. Korean J Hepatol. 2011;17:161–164.
- Song JS, Lee YJ, Kim KW, et al. Cholangiocarcinoma arising in von Meyenburg complexes: report of four cases. Pathol Int. 2008;58:503–512.
- Ryu Y, Matsui O, Zen Y, et al. Multicystic biliary hamartoma: imaging findings in four cases. Abdom Imaging. 2010;35:543–547.
- La'ulu SL, Roberts WL. Performance characteristics of five automated CA 19-9 assays. Am J Clin Pathol. 2007;127:436–440.
- Murohisa T, Sugaya H, Tetsuka I, et al. A case of common bile duct stone with cholangitis presenting an extraordinarily high serum CA19-9 value. Intern Med. 1992;31:516–520.
- Murray MD, Burton FR, Di Bisceglie AM. Markedly elevated serum CA 19-9 levels in association with a benign biliary stricture due to primary sclerosing cholangitis. J Clin Gastroenterol. 2007;41:115–117.
- Sheen-Chen SM, Sun CK, Liu YW, et al. Extremely elevated CA19-9 in acute cholangitis. Dig Dis Sci. 2007;52:3140–3142.
- Korkmaz M, Unal H, Selcuk H, et al. Extraordinarily elevated serum levels of CA 19-9 and rapid decrease after successful therapy: a case report and review of literature. Turk J Gastroenterol. 2010;21:461–463.
- Akdogan M, Sasmaz N, Kayhan B, et al. Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature. Tumori. 2001;87:337–339.
- Robertson AG, Davidson BR. Mirizzi syndrome complicating an anomalous biliary tract: a novel cause of a hugely elevated CA19-9. Eur J Gastroenterol Hepatol. 2007;19:167–169.
- Toomey DP, Swan N, Torreggiani W, et al. Autoimmune pancreatitis: medical and surgical management. JOP. 2007;8:335–343.
- Duraker N, Hot S, Polat Y, et al. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol. 2007;95:142–147.
- Aybek H, Aybek Z, Sinik Z, et al. Elevation of serum and urinary carbohydrate antigen 19-9 in benign hydronephrosis. Int J Urol. 2006;13:1380–1384.
- Kodama T, Satoh H, Ishikawa H, et al. Serum levels of CA19-9 in patients with nonmalignant respiratory diseases. J Clin Lab Anal. 2007;21:103–106.
- Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol. 1990;85:350–355.